The documents below contain clinical guideline recommendations or other recommendations that were used by the TEG to develop the quality standard statements and measures.
Ovarian cancer: the recognition and initial management of ovarian cancer. NICE clinical guideline 122 (2011; NHS Evidence accredited).
Trabectedin for the treatment of relapsed ovarian cancer. NICE technology appraisal guidance 222 (2011; NHS Evidence accredited).
Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. NICE technology appraisal guidance 91 (2005).
Guidance on the use of paclitaxel in the treatment of ovarian cancer. NICE technology appraisal guidance 55 (2003).
The Royal College of Radiologists (2012; NHS Evidence accredited). iRefer: Making the best use of clinical radiology: referral guidelines.
It is important that the quality standard is considered alongside current policy documents, including:
Department of Health (2011) Improving outcomes: a strategy for cancer.
Department of Health (1999) Improving outcomes in gynaecological cancers: the manual.
References included in the definitions and data sources sections can be found below:
Department of Health (2011) The operating framework for the NHS in England 2011/12.
National Cancer Intelligence Network (expected publication July 2012) National Cancer Outcomes and Services Dataset.
National Cancer Peer Review Programme (2008, updated 2011) Manual for cancer services: gynaecological measures.
NICE ovarian cancer audit support (NICE clinical guideline 122) (2011).
 NICE technology appraisal guidance 55, 91 and 222 were used in development only and were not used as evidence for the final standard.